Snider v. Upjohn Co.

115 F.R.D. 536, 1987 U.S. Dist. LEXIS 3023
CourtDistrict Court, E.D. Pennsylvania
DecidedApril 15, 1987
DocketCiv. A. No. 86-3625
StatusPublished
Cited by26 cases

This text of 115 F.R.D. 536 (Snider v. Upjohn Co.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Snider v. Upjohn Co., 115 F.R.D. 536, 1987 U.S. Dist. LEXIS 3023 (E.D. Pa. 1987).

Opinion

MEMORANDUM AND ORDER

BECHTLE, District Judge.

Presently before the court are plaintiff’s motion for class certification and defendants’ motion for summary judgment. For the reasons stated herein, plaintiff’s motion for class certification will be granted only as to Count I (claims under Sections 10(b) and 20 of the Securities Exchange Act of 1934, 15 U.S.C. §§ 78j(b) and 78t(a)) of the amended complaint. The class certification motion will be denied as to Counts II (common law fraud claim) and III (common law negligent misrepresentation claim) of the amended complaint, and those counts will be dismissed. Defendants’ motion for summary judgment will be denied.

I. FACTS

Plaintiff’s claim alleges that the defendants made material misrepresentations and omissions in public statements including an April 29, 1986 news release (“the news release”) and a Form 8-K filed on the same day with the Securities and Exchange Commission (“SEC”). These public statements concerned the results of Upjohn Co.’s (“Upjohn”) study of the efficacy and safety of the drug minoxidil in the treatment of male pattern baldness. Plaintiff contends that the alleged misrepresentations and omissions caused the price of Upjohn stock to increase. Plaintiff claims that in purchasing Upjohn stock she and the proposed class members relied on Upjohn’s public statements, or are deemed to have relied on such statements through the integrity of the market. Plaintiff asserts that when the alleged misrepresentations and omissions were disclosed to the public on June 17, 1986, the value of the Upjohn stock decreased. Plaintiff seeks compensatory damages from defendants for the money she and the members of the proposed class lost in their Upjohn securities trading from the date of the news release and filing of the Form 8-K, April 29, 1986, to the date of the public disclosure of the alleged misrepresentations and omissions, June 17, 1986.

Plaintiff seeks certification of a class action on behalf of all persons who purchased the common stock of Upjohn from April 29, 1986 through June 17, 1986, and held such stock on June 17, 1986, excluding defendants and persons acting in concert with them, members of the immediate families of the individual defendants and the officers and directors of the corporate defendants.

[538]*538Minoxidil is an antihypertensive peripheral vasodilator that has been marketed by Upjohn for several years, under the brand name of Loniten, as a treatment to be taken orally for severe high blood pressure. One of the common side effects of this drug, when it is taken orally, is the elongation, thickening and enhanced pigmentation of fine body hair on the temples, between the eyebrows, between the hairline and the eyebrows, on the sideburn area of the upper lateral cheek, and on the back, arms, legs and scalp.

In 1983, Upjohn began year-long studies and testing of the safety and efficacy of topically-applied minoxidil solutions in the treatment of male pattern baldness at 27 research centers throughout the United States. The purpose of these studies was to assess the efficacy and safety of applying 2% and 3% minoxidil solutions directly to the scalp for treatment of male pattern baldness. On December 19, 1985, following analysis of the data from the 27 research centers, Upjohn applied for Food and Drug Administration (“FDA”) approval to market a 2% topical minoxidil solution, under the name Rogaine, for treatment of male pattern baldness. The new drug application is still under review by the FDA.

Two days after the news release Upjohn’s common stock price rose to $174.25 per share and continued to increase after a 2-for-l stock split on May 2, 1986, to a high of $103.75 per share on June 13, 1986, and was at $101,625 per share on June 16, 1986.

On May 15, 1986, Upjohn received a letter (“the letter”) from William V. Purvis, Assistant to the Director of the FDA’s Division of Drug Advertising and Labeling. In that letter, Mr. Purvis characterized the Upjohn news release as “product labeling” within the meaning of Section 201(m) of the Federal Food Drug and Cosmetic Act (“FDCA”), 21 U.S.C. § 321 (1982). The letter went on to state that as labeling, the news release was false and misleading within the meaning of Section 502(a) of the FDCA, 21 U.S.C. § 352(a) (1982). That section governs product misbranding. On June 17, 1986, the letter was released to the public. On that day Upjohn’s common stock closed at $96.75 per share. This action was commenced on June 18, 1986, the day after the letter was publicized.

Plaintiff is apparently the only proposed class member that has been deposed and to that extent the court is limited to examining the basis for plaintiff’s claim. Moreover, other than plaintiff’s amended complaint, the parties have presented no other claims from proposed class members. As a result, the court is not in the best possible position to compare plaintiff’s cause of action with allegations of other investors. The parties, however, agree that plaintiff’s deposition transcript is dispositive of the present motions.

II. DISCUSSION

Class actions are a “particularly appropriate and desirable” way to resolve securities law claims and in a doubtful case courts should err in favor of allowing the class. Eisenberg v. Gagnon, 766 F.2d 770, 785 (3d Cir.), cert. denied, — U.S. -, 106 S.Ct. 342, 88 L.Ed.2d 290 (1985). Courts may approve class actions only after a “rigorous analysis” ensuring compliance with Fed.R.Civ.P. 23. General Telephone Co. v. Falcon, 457 U.S. 147, 161, 102 S.Ct. 2364, 2372, 72 L.Ed.2d 740 (1982); Glick v. E.F. Hutton & Co., Inc., 106 F.R.D. 446, 447 (E.D.Pa.1985).

When seeking class certification, plaintiff bears the burden of proving that the action satisfies all four threshold requirements set forth in Fed.R.Civ.P. 23(a) and also falls within one of the three categories of Rule 23(b). Eisen v. Carlisle & Jacqueline, 417 U.S. 156, 163, 94 S.Ct. 2140, 2145, 40 L.Ed.2d 732 (1974); Weiss v. York Hosp., 745 F.2d 786, 807 (3d Cir.1984), cert. denied, 470 U.S. 1060, 105 S.Ct. 1777, 84 L.Ed.2d 836 (1985). Rule 23(a) provides:

(a) Prerequisites to a Class Action. One or more members of a class may sue or be sued as representative parties on behalf of all only if (1) the class is so numerous that joinder of all members is impracticable, (2) there are questions of law or fact common to the class, (3) the [539]*539claims or defenses of the representative parties are typical of the claims or defenses of the class, and (4) the representative parties will fairly and adequately protect the interests of the class.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dale v. DaimlerChrysler Corp.
204 S.W.3d 151 (Missouri Court of Appeals, 2006)
Wachtel v. Guardian Life Insurance
223 F.R.D. 196 (D. New Jersey, 2004)
Chiang v. Veneman
213 F.R.D. 256 (Virgin Islands, 2003)
Samuel-Bassett v. Kia Motors America, Inc.
212 F.R.D. 271 (E.D. Pennsylvania, 2002)
Barabin v. Aramark Corp.
210 F.R.D. 152 (E.D. Pennsylvania, 2002)
In Re Kaiser Group International, Inc.
278 B.R. 58 (D. Delaware, 2002)
In Re United Companies Financial Corp.
276 B.R. 368 (D. Delaware, 2002)
Flannick v. First Union Home Equity Bank
134 F. Supp. 2d 389 (E.D. Pennsylvania, 2001)
Cheminova America Corporation v. Corker
779 So. 2d 1175 (Supreme Court of Alabama, 2000)
BNL Equity Corp. v. Pearson
10 S.W.3d 838 (Supreme Court of Arkansas, 2000)
Benevento v. Life USA Holding, Inc.
190 F.R.D. 359 (E.D. Pennsylvania, 2000)
In Re Fuqua Industries, Inc. Shareholder Litigation
752 A.2d 126 (Court of Chancery of Delaware, 1999)
Stewart v. Associates Consumer Discount Co.
183 F.R.D. 189 (E.D. Pennsylvania, 1998)
Morris v. Transouth Financial Corp.
175 F.R.D. 694 (M.D. Alabama, 1997)
Georgine v. Amchem Products, Inc.
157 F.R.D. 246 (E.D. Pennsylvania, 1994)
In Re Sahlen & Associates, Inc. Securities Litigation
773 F. Supp. 342 (S.D. Florida, 1991)
Squitieri v. Gould
133 F.R.D. 25 (E.D. Pennsylvania, 1990)
Moskowitz v. Lopp
128 F.R.D. 624 (E.D. Pennsylvania, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
115 F.R.D. 536, 1987 U.S. Dist. LEXIS 3023, Counsel Stack Legal Research, https://law.counselstack.com/opinion/snider-v-upjohn-co-paed-1987.